False-negative rate after positron emission tomography/computer tomography scan for mediastinal staging in ci stage non-small-cell lung cancer

European Journal of Cardio-thoracic Surgery

Volumn 42, Issue 1, 2012, Pages 93-100

  Gómez caro, Abel ^a   Boada, Marc ^a   Cabañas, Maria ^a   Sanchez, Marcelo ^a   Arguis, Pedro ^a   Lomeña, Francisco ^a   Ramirez, Josep ^a   Molins, Laureano ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Lung cancer; Mediastinal metastases; PET; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADENOCARCINOMA; ADULT; ARTERY DIAMETER; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FALSE NEGATIVE RESULT; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG VEIN; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM METASTASIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY ARTERY; THORACOTOMY; THORAX RADIOGRAPHY; TREATMENT CONTRAINDICATION; TUMOR VOLUME; AGED; CLINICAL TRIAL; INCIDENCE; LABORATORY DIAGNOSIS; LUNG RESECTION; LUNG TUMOR; LYMPH NODE METASTASIS; MEDIASTINUM TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; RISK FACTOR; SCINTISCANNING; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FALSE NEGATIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INCIDENCE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; PNEUMONECTOMY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RISK FACTORS;

EID: 84871703581     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezr272     Document Type: Article

References (24)

1. Albain KS, Swann RS, Rusch VW, Turrisi AT III, Shepherd FA, Smith C et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379-86.
2. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-8.
3. Van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359: 1388-93.
4. Verhagen AF, Bootsma GP, Tjan-Heijnen VC, van der Wilt GJ, Cox AL, Brouwer MH et al. FDG-PET in staging lung cancer: how does it change the algorithm? Lung Cancer 2004;44:175-81.
5. Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009;361:32-9.
6. Port JL, Andrade RS, Levin MA, Korst RJ, Lee PC, Becker DE et al. Positron emission tomographic scanning in the diagnosis and staging of non-small cell lung cancer 2 cm in size or less. J Thorac Cardiovasc Surg 2005;130:1611-5.
7. De Leyn P, Lardinois D, Van Schil PE, Rami-Porta R, Passlick B, Zielinski M et al. ESTS guidelines for preoperative lymph node staging for nonsmall cell lung cancer. Eur J Cardiothorac Surg 2007;32:1-8.
8. Douillard JY, Rosell R, De Lena M, Riggi M, Hurteloup P, Mahe MA. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys 2008;72:695-701.
9. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-27.
10. Al-Sarraf N, Aziz R, Gately K, Lucey J, Wilson L, McGovern E et al. Pattern and predictors of occult mediastinal lymph node involvement in nonsmall cell lung cancer patients with negative mediastinal uptake on positron emission tomography. Eur J Cardiothorac Surg 2008;33:104-9.
11. Stiles BM, Servais EL, Lee PC, Port JL, Paul S, Altorki NK. Point: clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging. J Thorac Cardiovasc Surg 2009;137:13-9.
12. Gomez-Caro A, Garcia S, Reguart N, Arguis P, Sanchez M, Gimferrer JM et al. Incidence of occult mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan. Eur J Cardiothorac Surg 2010;37:1168-74.
13. Brunelli A, Charloux A, Bolliger CT, Rocco G, Sculier JP, Varela G et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J 2009;34:17-41.
14. Goldstraw P. IASLC Staging Manual in Thoracic Oncology. Orange Park, FL: Editorial Rx Press, 2009.
15. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011;6:244-85.
16. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verschakelen JA, Nackaerts KL et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung Cancer Group. Chest 1997;112:1480-6.
17. Melek H, Gunluoglu MZ, Demir A, Akin H, Olcmen A, Dincer SI. Role of positron emission tomography in mediastinal lymphatic staging of nonsmall cell lung cancer. Eur J Cardiothorac Surg 2008;33:294-9.
18. Ketchedjian A, Daly BD, Fernando HC, Florin L, Hunter CJ, Morelli DM et al. Location as an important predictor of lymph node involvement for pulmonary adenocarcinoma. J Thorac Cardiovasc Surg 2006;132:544-8.
19. Bryant AS, Cerfolio RJ. The clinical stage of non-small cell lung cancer as assessed by means of fluorodeoxyglucose-positron emission tomographic/ computed tomographic scanning is less accurate in cigarette smokers. J Thorac Cardiovasc Surg 2006;132:1363-8.
20. Schuchert MJ, Abbas G, Pennathur A, Nason KS, Wilson DO, Luketich JD et al. Sublobar resection for early-stage lung cancer. Semin Thorac Cardiovasc Surg 2010;22:22-31.
21. Donington JS, Colson YL. Sex and gender differences in non-small cell lung cancer. Semin Thorac Cardiovasc Surg 9999;23:137-45.
22. Radzikowska E, Langfort R, Giedronowicz D. Estrogen and progesterone receptors in non-small cell lung cancer patients. Ann Thorac Cardiovasc Surg 2002;8:69-73.
23. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol 2002;13:1087-93.
24. Slatore CG, Chien JW, Au DH, Satia JA, White E. Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J Clin Oncol 9999;28:1540-6.